Display options
Cite
Tan JM, Foo JB, Fakurazi S, et al. Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes. Beilstein J Nanotechnol. 2015;6:243-53doi: 10.3762/bjnano.6.23.
Tan, J. M., Foo, J. B., Fakurazi, S., & Hussein, M. Z. (2015). Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes. Beilstein journal of nanotechnology, 6243-53. https://doi.org/10.3762/bjnano.6.23
Tan, Julia M, et al. "Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes." Beilstein journal of nanotechnology vol. 6 (2015): 243-53. doi: https://doi.org/10.3762/bjnano.6.23
Tan JM, Foo JB, Fakurazi S, Hussein MZ. Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes. Beilstein J Nanotechnol. 2015 Jan 22;6:243-53. doi: 10.3762/bjnano.6.23. eCollection 2015. PMID: 25671168; PMCID: PMC4311623.
Copy Download .nbib Format: NLM
Share it on

Beilstein J Nanotechnol. 2015 Jan 22;6:243-53. doi: 10.3762/bjnano.6.23. eCollection 2015.

Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes.

Beilstein journal of nanotechnology

Julia M Tan, Jhi Biau Foo, Sharida Fakurazi, Mohd Zobir Hussein

Affiliations

  1. Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
  2. Laboratory of Molecular Biomedicine, Institute of Bioscience (IBS), Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
  3. Laboratory of Vaccine and Immunotherapeutics, Institute of Bioscience (IBS), Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia, ; Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

PMID: 25671168 PMCID: PMC4311623 DOI: 10.3762/bjnano.6.23

Abstract

This work explores the potential use of commercially obtained, carboxylated, single-walled carbon nanotubes (SWCNT-COOH) as nanocarriers for the antiparkinson drug, levodopa (LD). The resulting nanohybrid was characterized using materials characterization methods including Fourier transform infrared spectroscopy, Raman spectroscopy, elemental analysis, UV-vis spectroscopy and scanning electron microscopy. The results showed that SWCNT-COOH were able to form supramolecular complexes with LD via a π-π stacking interaction and exhibited favourable, slow, sustained-release characteristics as a drug carrier with a release period over more than 20 h. The results obtained from the drug release studies of LD at different pH values showed that the LD-loaded nanohybrid is pH activated. The release kinetics of LD from SWCNT-COOH were well-described by a pseudo-second-order kinetic model. A cytotoxicity assay of the synthesized nanohybrid was also carried out in PC12 cell lines (a widely used, in vitro Parkinson's model for neurotoxicity studies) using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in order to investigate their possible effects on normal neuronal cells in vitro. It was found that the synthesized nanohybrid did not compromise the cell viability and the PC12 cells remained stable throughout the experiments up to 72 h after treatment.

Keywords: MTT assay; PC12 cells; Parkinson’s disease; carboxylic acid-functionalized single-walled carbon nanotubes; levodopa; nanomedicine; sustained release

References

  1. Int J Nanomedicine. 2012;7:5745-56 - PubMed
  2. Nano Lett. 2010 Nov 10;10(11):4619-26 - PubMed
  3. Curr Drug Deliv. 2011 May;8(3):235-44 - PubMed
  4. Chem Soc Rev. 2012 Apr 7;41(7):2696-706 - PubMed
  5. J Pharmacol Exp Ther. 2003 Feb;304(2):792-800 - PubMed
  6. Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:41-9 - PubMed
  7. Toxicol Lett. 2007 Jan 30;168(2):121-31 - PubMed
  8. Adv Drug Deliv Rev. 2011 Nov;63(14-15):1332-9 - PubMed
  9. Clin Neuropharmacol. 1994 Feb;17(1):38-44 - PubMed
  10. J Med Chem. 2014 Jul 10;57(13):5679-85 - PubMed
  11. Handb Clin Neurol. 2007;83:107-28 - PubMed
  12. J Am Chem Soc. 2003 Dec 10;125(49):15174-82 - PubMed
  13. Prog Neurobiol. 2009 Aug;88(4):272-85 - PubMed
  14. Int J Nanomedicine. 2012;7:905-14 - PubMed
  15. ACS Nano. 2009 Feb 24;3(2):307-16 - PubMed
  16. Chem Cent J. 2013 Apr 20;7(1):72 - PubMed
  17. Prog Neurobiol. 2007 Jan;81(1):29-44 - PubMed
  18. Int J Pharm. 2011 Feb 28;405(1-2):153-61 - PubMed
  19. Acc Chem Res. 2013 Apr 16;46(4):1029-38 - PubMed
  20. Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S31-4 - PubMed
  21. Int J Mol Sci. 2014 Apr 09;15(4):5916-27 - PubMed
  22. J Mol Biol. 1964 May;8:660-8 - PubMed
  23. Int J Nanomedicine. 2014 Jun 26;9:3137-49 - PubMed
  24. Nano Lett. 2010 Mar 10;10(3):751-8 - PubMed

Publication Types